AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10381993 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nalmefene
Number of subjects: 176
Study 10381993 — intervention group
Group type: COMPARATOR
Intervention: 2 mg naloxone
Number of subjects: 176
Study 8896541 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titer vaccine
Number of subjects: 513
Study 8896541 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-titer vaccine
Number of subjects: 513
Study 8896541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 513
Study 6359486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciramadol 20 mg
Number of subjects: 180
Study 6359486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciramadol 60 mg
Number of subjects: 180
Study 6359486 — intervention group
Group type: COMPARATOR
Intervention: Codeine 60 mg
Number of subjects: 180
Study 31672121 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of barriers in the participant's environment and multimorbidity
Number of subjects: 0
Study 31672121 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain on the VAS scale ≥3 points and older age
Number of subjects: 0
Study 29787488 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral lenses with various initial post-lens tear thickness (PoLTT) values ranging from 74 to 543 μm
Number of subjects: 0
Study 26862038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 24
Study 26862038 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Therapy (ET)
Number of subjects: 24
Study 26862038 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study 25157543 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein and high cereal fiber diet
Number of subjects: 76
Study 25157543 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate protein and moderate cereal fiber diet
Number of subjects: 76
Study 25157543 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein and low cereal fiber diet
Number of subjects: 76
Study 25157543 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored dietary supplements for twice-daily consumption
Number of subjects: 76
Study 25157543 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 76
Study 22121190 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (300 mg once daily)
Number of subjects: 39
Study 22121190 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (400 mg twice daily)
Number of subjects: 39
Study 21108824 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-Personal Counseling
Number of subjects: 0
Study 21108824 — intervention group
Group type: COMPARATOR
Intervention: Selective Serotonin Reuptake Inhibitors
Number of subjects: 0
Study 17418297 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of autologous endothelial progenitor cells (EPCs) plus conventional therapy
Number of subjects: 0
Study 17418297 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 0
Study 16720149 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene mesh (MR)
Number of subjects: 20
Study 16720149 — intervention group
Group type: COMPARATOR
Intervention: Conventional sutures (CR)
Number of subjects: 20
Study 14744170 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR 150 mg b.i.d. for 4 weeks
Number of subjects: 42
Study 14744170 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 42
Study 10735706 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous pulmonary perfusion during total cardiopulmonary bypass (perfused group)
Number of subjects: 30
Study 10735706 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiopulmonary bypass (control group)
Number of subjects: 30
Study 8737145 — intervention group
Group type: EXPERIMENTAL
Intervention: Trovafloxacin 100 mg
Number of subjects: 0
Study 8737145 — intervention group
Group type: EXPERIMENTAL
Intervention: Trovafloxacin 300 mg
Number of subjects: 0
Study 8737145 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of trovafloxacin
Number of subjects: 0
Study 1524757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulation after awakening
Number of subjects: 26
Study 1524757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of 10 mg nifedipine after awakening
Number of subjects: 26
Study 1524757 — intervention group
Group type: COMPARATOR
Intervention: Remaining supine
Number of subjects: 26
Study 2862057 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 120 mg b.d. for one week
Number of subjects: 20
Study 2862057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31751607 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light exposure (30-min pulses daily for 6 weeks, peak λ = 469 nm)
Number of subjects: 32
Study 31751607 — intervention group
Group type: COMPARATOR
Intervention: Amber placebo light (30-min pulses daily for 6 weeks, peak λ = 578 nm)
Number of subjects: 32
Study 30272379 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiglottic catheter and nasal mask during physiology night
Number of subjects: 28
Study 30272379 — intervention group
Group type: COMPARATOR
Intervention: Standard in-laboratory polysomnography
Number of subjects: 28
Study 27776201 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistrategy inference intervention (explicit instruction in 4 inference strategies)
Number of subjects: 66
Study 26542467 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective Vitality Scale (SVS)
Number of subjects: 439
Study 23490474 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.5 μg/kg bolus followed by infusion of 0.0625-0.250 μg/kg/min)
Number of subjects: 17
Study 23490474 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (2 μg/kg intravenously followed by infusion of 0.03-0.06 μg/kg/min)
Number of subjects: 17
Study 21376434 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mL/day of olive oil with high phenolic content (366 mg/kg)
Number of subjects: 200
Study 21376434 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mL/day of olive oil with medium phenolic content (164 mg/kg)
Number of subjects: 200
Study 21376434 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mL/day of olive oil with low phenolic content (2.7 mg/kg)
Number of subjects: 200
Study 21376434 — intervention group
Group type: COMPARATOR
Intervention: Control group (no olive oil intervention)
Number of subjects: 200
Study 19515553 — intervention group
Group type: EXPERIMENTAL
Intervention: Canfosfamide (CAN) 1000 mg/m(2) IV q 3 weeks
Number of subjects: 461
Study 19515553 — intervention group
Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD) 50 mg/m(2) IV q 4 weeks
Number of subjects: 461
Study 19515553 — intervention group
Group type: COMPARATOR
Intervention: Topotecan (TOPO) 1.5 mg/m(2) IV d1-5 q 3 weeks
Number of subjects: 461
Study 17529848 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of mainstream performance (AMP)
Number of subjects: 26
Study 17529848 — intervention group
Group type: EXPERIMENTAL
Intervention: SIFTER instruments
Number of subjects: 26
Study 17529848 — intervention group
Group type: EXPERIMENTAL
Intervention: Reynell and Schlichting tests
Number of subjects: 26
Study 15048739 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colonic resection (LCR)
Number of subjects: 210
Study 15048739 — intervention group
Group type: COMPARATOR
Intervention: Open colonic resection (OCR)
Number of subjects: 210
Study 11555521 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine pretreatment (7‐min infusion of adenosine, total 650 microg/kg)
Number of subjects: 30
Study 11555521 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 30
Study 9777976 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg/g becaplermin gel
Number of subjects: 922
Study 9777976 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg/g becaplermin gel
Number of subjects: 922
Study 9777976 — intervention group
Group type: COMPARATOR
Intervention: becaplermin gel
Number of subjects: 922
Study 9777976 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 922
Study 9777976 — intervention group
Group type: COMPARATOR
Intervention: Good ulcer care alone
Number of subjects: 922
Study 7931184 — intervention group
Group type: EXPERIMENTAL
Intervention: VCA-IgG avidity determination
Number of subjects: 105
Study 7931184 — intervention group
Group type: EXPERIMENTAL
Intervention: EA-IgG avidity determination
Number of subjects: 105
Study 3653052 — intervention group
Group type: EXPERIMENTAL
Intervention: CBZ-controlled release (CR)
Number of subjects: 0
Study 3653052 — intervention group
Group type: COMPARATOR
Intervention: Conventional carbamazepine (CBZ)
Number of subjects: 0
Study 3653052 — intervention group
Group type: COMPARATOR
Intervention: Nonmedication control group
Number of subjects: 0
Study 31665507 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and education plus cervico‐mandibular manual therapy
Number of subjects: 61
Study 31665507 — intervention group
Group type: COMPARATOR
Intervention: Exercise and education alone
Number of subjects: 61
Study 30982940 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing feedback during a 12-month maintenance walking program (telephone calls, biofeedback via pedometer, progressive goal setting)
Number of subjects: 86
Study 30982940 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (no feedback)
Number of subjects: 86
Study 28079566 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal system (SAFERsleep)
Number of subjects: 40
Study 28079566 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 40
Study 26318558 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 86
Study 26318558 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-109
Number of subjects: 86
Study 26318558 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Rifampicin and SQ-109 combined
Number of subjects: 86
Study 23636235 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight change after 1 month of ART
Number of subjects: 3389
Study 23636235 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss ≥2.5% at 1 month of ART
Number of subjects: 3389
Study 23636235 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss at 1 month of ART
Number of subjects: 3389
Study 21757505 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-similarity displays
Number of subjects: 0
Study 21757505 — intervention group
Group type: COMPARATOR
Intervention: High-similarity distractors
Number of subjects: 0
Study 21757505 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed displays
Number of subjects: 0
Study 21757505 — intervention group
Group type: EXPERIMENTAL
Intervention: Similarity estimates from a computer vision model
Number of subjects: 0
Study 21757505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cases where model and human rankings agreed
Number of subjects: 0
Study 18836727 — intervention group
Group type: EXPERIMENTAL
Intervention: Aberration corrected hydrophilic acrylic intraocular lens (IOL) for MICS
Number of subjects: 0
Study 18836727 — intervention group
Group type: COMPARATOR
Intervention: One-piece hydrophobic acrylic IOL
Number of subjects: 0
Study 16847681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16847681 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.1 mg/70 kg
Number of subjects: 12
Study 16847681 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.2 mg/70 kg
Number of subjects: 12
Study 16847681 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.4 mg/70 kg
Number of subjects: 12
Study 15231917 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood Asthma Coalition (NAC) intervention
Number of subjects: 249
Study 15231917 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 249
Study 12618922 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol (synthetic cannabinoid)
Number of subjects: 0
Study 12618922 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabinoids (general)
Number of subjects: 0
Study 10948356 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-bound polysaccharide (PSK)
Number of subjects: 751
Study 8853263 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy
Number of subjects: 0
Study 8853263 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth triple therapy
Number of subjects: 0
Study 8853263 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor triple therapy
Number of subjects: 0
Study 8853263 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy
Number of subjects: 0
Study 1333740 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 8
Study 1333740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 4014120 — intervention group
Group type: EXPERIMENTAL
Intervention: Random-zero sphygmomanometer
Number of subjects: 0
Study 4014120 — intervention group
Group type: COMPARATOR
Intervention: Standard mercury sphygmomanometer
Number of subjects: 0
Study 30921552 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt (300g/d containing Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12)
Number of subjects: 44
Study 30921552 — intervention group
Group type: COMPARATOR
Intervention: Regular yogurt (control group)
Number of subjects: 44
Study 30921552 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt (300g/d)
Number of subjects: 44
Study 28858387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/day plus atorvastatin 40 mg/day
Number of subjects: 65
Study 28858387 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 80 mg/day
Number of subjects: 65
Study 27294589 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost administered once daily to both eyes
Number of subjects: 28
Study 27294589 — intervention group
Group type: COMPARATOR
Intervention: Bromfenac sodium hydrate administered twice daily to one eye
Number of subjects: 28
Study 27294589 — intervention group
Group type: COMPARATOR
Intervention: Flavin adenine dinucleotide sodium administered twice daily to the other eye
Number of subjects: 28
Study 27294589 — intervention group
Group type: COMPARATOR
Intervention: Both groups (NSAID and control)
Number of subjects: 28
Study 27294589 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID (Bromfenac sodium hydrate)
Number of subjects: 28
Study 25240971 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg zinc/day for 8 weeks)
Number of subjects: 35
Study 25240971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 22846674 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile/kinesthetic stimulation (TKS)
Number of subjects: 20
Study 22846674 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 20925938 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg vildagliptin once daily
Number of subjects: 32
Study 20925938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 18567436 — intervention group
Group type: EXPERIMENTAL
Intervention: Artequick (3.2 mg/Kg/day of artemisinin, 16 mg/Kg/day of piperaquine, and 0.16 mg/Kg/day of primaquine)
Number of subjects: 130
Study 18567436 — intervention group
Group type: COMPARATOR
Intervention: artesunate-mefloquine (4 mg/Kg/day of artesunate, 8 mg/Kg/day of mefloquine)
Number of subjects: 130
Study 15838471 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch angioplasty with polyester urethane (Vascular‐patch, B. Braun Medical AG)
Number of subjects: 404
Study 15838471 — intervention group
Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 404
Study 11864676 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-tip test measuring straining angle
Number of subjects: 274
Study 11864676 — intervention group
Group type: EXPERIMENTAL
Intervention: POP-Q system assessment at point Aa
Number of subjects: 274
Study 11864676 — intervention group
Group type: EXPERIMENTAL
Intervention: POP-Q system assessment at point Ba
Number of subjects: 274
Study 10668449 — intervention group
Group type: EXPERIMENTAL
Intervention: NPS 1506 (doses ranging from 5-100 mg i.v.)
Number of subjects: 0
Study 10668449 — intervention group
Group type: EXPERIMENTAL
Intervention: NPS 1506 (neuroprotective doses of approximately 0.1-1.0 mg/kg)
Number of subjects: 0
Study 10668449 — intervention group
Group type: EXPERIMENTAL
Intervention: NPS 1506 (100 mg i.v.)
Number of subjects: 0
Study 10668449 — intervention group
Group type: EXPERIMENTAL
Intervention: NPS 1506 (doses producing behavioral toxicity)
Number of subjects: 0
Study 7546487 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripton used in conjunction with Opalux and the ultrafine compact-filled, experimental visible light cured resin composite M221784 (ICI Dental)
Number of subjects: 0
Study 7546487 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched restorations with the other resin composite)
Number of subjects: 0
Study 2126739 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Estramustine phosphate orally
Number of subjects: 0
Study 2126739 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C by i.v. injection every 6 weeks
Number of subjects: 0
Study 7254509 — intervention group
Group type: EXPERIMENTAL
Intervention: Monaural presentation of single digits to right ear
Number of subjects: 0
Study 7254509 — intervention group
Group type: EXPERIMENTAL
Intervention: Monaural presentation of single digits to left ear
Number of subjects: 0
Study 7254509 — intervention group
Group type: COMPARATOR
Intervention: Dichotic presentation (not directly tested in this study)
Number of subjects: 0
Study 31388698 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 35
Study 31388698 — intervention group
Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 35
Study 28492196 — intervention group
Group type: EXPERIMENTAL
Intervention: Munident (herbal) dentifrice
Number of subjects: 40
Study 28492196 — intervention group
Group type: COMPARATOR
Intervention: Standard toothpaste
Number of subjects: 40
Study 25588590 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ultrasonic phacoemulsification with anterior chamber maintainer (ACM)
Number of subjects: 60
Study 25588590 — intervention group
Group type: COMPARATOR
Intervention: Continuous ultrasonic phacoemulsification without anterior chamber maintainer (ACM)
Number of subjects: 60
Study 23121340 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerodynamic drag (F(d)) measured during skiing
Number of subjects: 9
Study 23121340 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy dissipation (E(d))
Number of subjects: 9
Study 23121340 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical modeling of drag coefficient
Number of subjects: 9
Study 21635243 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (target 300 mg/day) + Atorvastatin 40 mg/day
Number of subjects: 119
Study 21635243 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (target 4 mg/kg per day) + Atorvastatin 40 mg/day
Number of subjects: 119
Study 19489707 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized acupuncture points according to Traditional Chinese Medicine
Number of subjects: 31
Study 19489707 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed, standard acupuncture points
Number of subjects: 31
Study 19489707 — intervention group
Group type: COMPARATOR
Intervention: Sham nonpenetrating acupuncture
Number of subjects: 31
Study 16861717 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical and surgical coronary disease treatments
Number of subjects: 1950
Study 16861717 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased treatment levels to reach 80% of eligible patients
Number of subjects: 1950
Study 16861717 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximizing treatment uptake of eligible heart failure patients
Number of subjects: 1950
Study 16861717 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins and secondary prevention therapies
Number of subjects: 1950
Study 15272110 — intervention group
Group type: EXPERIMENTAL
Intervention: Melissa officinalis 600 mg
Number of subjects: 18
Study 15272110 — intervention group
Group type: EXPERIMENTAL
Intervention: Melissa officinalis 300 mg
Number of subjects: 18
Study 15272110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11458050 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 957
Study 11458050 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG plus isoniazid
Number of subjects: 957
Study 11458050 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin
Number of subjects: 957
Study 11458050 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 957
Study 9567003 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed carrots and spinach
Number of subjects: 8
Study 9567003 — intervention group
Group type: COMPARATOR
Intervention: Raw carrots and spinach
Number of subjects: 8
Study 9567003 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed vegetables
Number of subjects: 8
Study 8049912 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglyconate (Maxon)
Number of subjects: 100
Study 8049912 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene
Number of subjects: 100
Study 2845564 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (30 mg/kg/d) for one week
Number of subjects: 30
Study 2845564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19488540 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Bupivacaine with 1:200,000 epinephrine
Number of subjects: 37
Study 19488540 — intervention group
Group type: COMPARATOR
Intervention: 0.5% Ropivacaine
Number of subjects: 37
Study 573564 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (1.25 mg)
Number of subjects: 185
Study 573564 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 185
Study 573564 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (5 or 10 mg)
Number of subjects: 185
Study 573564 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 185
Study 30685496 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop conference recommendations
Number of subjects: 142
Study 30685496 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunities for scholarship
Number of subjects: 142